STOCK TITAN

Edwards Lifesciences SVP has 253 shares withheld

Edwards Lifesciences SVP and Corporate Controller had a small number of shares withheld to cover taxes on vested equity, with a modest remaining direct holding reported.

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Edwards Lifesciences Corp (EW) reported a routine insider equity event for Andrew M. Dahl, SVP and Corporate Controller. On September 13, 2026, 253 shares of common stock were withheld by the company at $84.37 per share to satisfy tax withholding obligations upon vesting, leaving him with 14,615.41 directly held shares.

Positive

  • None.

Negative

  • None.
Insider Dahl Andrew M.
Role SVP, Corporate Controller
Type Security Shares Price Value
Tax Withholding Common Stock F1 253 $84.37 $21K
Holdings After Transaction: Common Stock — 14,615.41 shares (Direct)
Footnotes (1)
  1. F1. Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e).
Shares withheld for taxes 253 shares Withheld on September 13, 2026 to satisfy tax withholding obligations
Per-share price used for withholding $84.37 per share Valuation for 253 shares withheld for tax obligations
Direct holdings after transaction 14,615.41 shares Common stock directly owned by Andrew M. Dahl after the withholding
beneficial ownership financial
"This Form 4 reflects changes in beneficial ownership only"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
tax withholding obligations financial
"shares withheld by the Issuer to satisfy tax withholding obligations incident"
Rule 16b-3(e) regulatory
"obligations incident to the vesting of securities in accordance with Rule 16b-3(e)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did EW report for Andrew M. Dahl on this Form 4?

The filing reports that 253 shares of Edwards Lifesciences common stock were withheld on September 13, 2026 to satisfy tax withholding obligations related to vesting equity awards.

Was the EW insider transaction an open market sale or a tax withholding event?

It was a tax withholding event, not an open market sale. The shares were withheld by the issuer to satisfy tax obligations incident to vesting under Rule 16b-3(e).

At what price were the 253 EW shares withheld for taxes?

The 253 shares were valued at a price of $84.37 per share in connection with the tax withholding transaction on September 13, 2026.

How many EW shares does Andrew M. Dahl hold directly after this transaction?

After the withholding of 253 shares for taxes, Andrew M. Dahl directly holds 14,615.41 shares of Edwards Lifesciences common stock, as reported in the Form 4.

Was a Rule 10b5-1 trading plan involved in this EW Form 4 transaction?

No. The filing indicates no Rule 10b5-1 trading plan was reported for this transaction; the document-level 10b5-1 checkbox is not marked as being under such a plan.

Does this EW Form 4 reflect all securities owned by the reporting person?

No. The remarks state it reflects changes in beneficial ownership only and does not identify other securities of Edwards Lifesciences beneficially owned by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dahl Andrew M.

(Last)(First)(Middle)
ONE EDWARDS WAY

(Street)
IRVINE CALIFORNIA 92614

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP, Corporate Controller
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/13/2026F(1)253D$84.3714,615.41D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e).
Remarks:
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact09/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading